Novo Nordisk: Liraglutide in obesity: a sizeable opportunity

 Neutral, FV DKK920

News published on March Tuesday 5, 2013
Share on

When assessing the opportunity relative to the size of Novo-Nordisk, the liraglutide programme in obesity is probably the most significant challenge facing a European player in 2013. However the steps to be taken to reach this windfall and the first phase III data expected in coming weeks need to be totally unambiguous, especially in terms of tolerance, in order to make the chances of success real.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities